By Spondylitis Association of America
Helpful Hints is a recurring feature, aimed at sharing our community’s knowledge and experiences. Living with spondyloarthritis can be difficult and challenging at times, however, throughout the process we can learn a lot about ourselves, our surroundings, and life in general. In this installment, we asked our online community, “If you have learned anything special about life or human nature as a result of spondyloarthritis, what is it?”
According to findings from a recent cohort study, the combined use of nonsteroidal anti-inflammatory drugs (NSAIDs) and tumor necrosis factor (TNF) inhibitors, may help slow the progression of damage to the spine in ankylosing spondylitis, mitigating some of the effects of the disease.
Researchers at Boston University are conducting a survey to help learn about how people with ankylosing spondylitis and related conditions choose medications. The survey will take 15-20 minutes to complete. Those who finish the survey may win one of five $50 gift cards.
Helpful Hints is a recurring feature, aimed at sharing our community’s knowledge and experiences. In this installment, we asked our online community, “Do you practice self-care? What do you do to treat yourself?"
On March 28, 2019, the U.S. FDA announced the approval of the TNF inhibitor, certolizumab pegol (CIMZIA®) for the treatment for non-radiographic axial spondyloarthritis (nr-axSpA.) This is the first, and currently only biologic agent to gain approval for nr-axSpA in the U.S., providing those living with the condition access to a new class of medication.
Visit our careers page for available positions
16360 Roscoe Blvd. Ste. 100Van Nuys, CA 91406
(800) 777-8189 U.S. only
or (818) 892-1616*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.